SEC Tracker
Get the app

Zymeworks ZYME

Zymeworks Q3 FY23: revenue $16.5M; diluted EPS −$0.41

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.4
Material contract

Key figures from this report

These are the numbers Zymeworks reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$16.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$28.7MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.41No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$94.3MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$42.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Zymeworks files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Anaptysbio ANAB public float $633M, Dec 31, 2025
  2. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
  3. ImmunityBio IBRX public float $690M, Jun 30, 2025
  4. Evoke Pharma EVOK
  5. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.